Glaukos (GKOS) vs 10x Genomics (TXG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
10x Genomics (TXG) has outperformed Glaukos (GKOS) over the past year, gaining 540.3% versus a gain of 84.1%. Over five years, GKOS leads with a +259.9% price change compared with -49.2% for TXG. 10x Genomics is the larger company by market cap ($10.07 billion vs $9.51 billion), about 1.1 times the size, while Glaukos is growing revenue faster (+32.3% vs +5.2%).
On valuation, Glaukos trades at a lower forward P/E (308.1x vs 1008.0x for 10x Genomics). 10x Genomics converts more of its revenue into profit, with a net margin of -6.8% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | TXG |
|---|---|---|
| Share price | $161.29 | $77.28 |
| Market cap | $9.51B | $10.07B |
| 1-day change | -6.32% | +1.55% |
| YTD return | +42.85% | +373.82% |
| 1-year return | +84.14% | +540.27% |
| 5-year return | +259.86% | -49.25% |
| Forward P/E | 308.06 | — |
| EPS (TTM) | $-3.26 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $507.44M | $642.82M |
| Revenue growth (YoY) | +32.33% | +5.25% |
| Net income (latest FY) | $-187.69M | $-43.54M |
| Gross margin | 55.72% | 69.05% |
| Operating margin | -39.33% | -9.49% |
| Net margin | -36.99% | -6.77% |
| 52-week high | $191.62 | $102.81 |
| 52-week low | $73.16 | $11.16 |
| Distance from 52-week high | -15.83% | -24.83% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +23.19% | -12.69% |
| Average volume | 831.71K | 3.29M |
| Shares outstanding | 58.98M | 120.21M |
| Employees | 1,094 | 1,178 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TXG has outperformed GKOS by 456.1 percentage points over the past year.
- 10x Genomics is more profitable, keeping -6.8 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +5.25%).
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Healthcare · Medical Devices · 1,094 employees
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Healthcare · Medical Devices · 1,178 employees
GKOS vs TXG FAQ
Which is bigger, Glaukos or 10x Genomics?
10x Genomics (TXG) is larger, with a market capitalization of $10.07B compared with $9.51B for Glaukos (GKOS).
Which stock has performed better over the past year, GKOS or TXG?
TXG returned +540.27% over the past 12 months, compared with +84.14% for GKOS (price return, excluding dividends). Past performance does not predict future results.
Are Glaukos and 10x Genomics in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.